Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac (R)): a case report

ÜZER F., ÇİLLİ A.

MEDICAL GAS RESEARCH, vol.12, no.2, pp.67-68, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.4103/2045-9912.326003
  • Journal Name: MEDICAL GAS RESEARCH
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.67-68
  • Keywords: adverse event, allergy, computed tomography, infiltrations, SARS-CoV-2, side effect, systemic inflammation, vaccine
  • Akdeniz University Affiliated: Yes

Abstract

A 76-year-old female received a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac, Sinovac (R), Beijing, China) and subsequently experienced chest discomfort. A computed tomography performed 1 day after vaccination showed multiple infiltrations in both lungs and ground-glass shadows in both lung fields. Her fingertip oxygen saturation was 81% and there was widespread wheezing on physical examination. Based on these findings, the patient was hospitalized with a preliminary diagnosis of drug-induced pneumonitis and acute asthma exacerbation due to a SARS-CoV-2 vaccine. During her hospitalization, 40 mg/d systemic steroid, 4 times a day salbutamol nebulized, 2 L/min inhaled oxygen therapy and 400 mg/d moxifloxacin intravenous were administered for 5 days. One month later, the thorax computed tomography scan revealed that the previous findings were almost completely regressed.